Literature DB >> 27545416

Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study.

Luca Ceriani1, Sally Barrington2, Alberto Biggi3, Bogdan Malkowski4, Ur Metser5, Annibale Versari6, Maurizio Martelli7, Andrew Davies8, Peter W Johnson8, Emanuele Zucca9, Stéphane Chauvie10.   

Abstract

The International Extranodal Lymphoma Study Group (IELSG)-37 is a prospective randomized trial assessing the role of consolidation mediastinal radiotherapy after immunochemotherapy to patients with newly diagnosed primary mediastinal large B-cell lymphoma (PMBCL). It is a positron emission tomography (PET) response-guided study where patients obtaining a complete metabolic response on an end-of-therapy PET-computed tomography (CT) scan evaluated by a central review are randomized to receive radiotherapy or no further treatment. The aims of this study were to measure agreement between reviewers reporting PET-CT scans for this trial and to determine the effect of training upon concordance rates. The review panel comprised 6 experienced nuclear physicians who read PET-CT scans using the 5-point Deauville scale. Interobserver agreement (IOA) was measured at 4 time points: after a blinded review of a "training set" of 20 patients with PMBCL from the previous IELSG-26 study (phase 1); after the first 10 clinical cases enrolled in the IELSG-37 (phase 2); and after 2 further groups of 50 (phase 3) and 40 clinical cases (phase 4). After feedback from the training set and the first 10 cases, a meeting was held to discuss interpretation, and a detailed set of instructions for the review procedure was agreed and acted upon. Between 2012 and 2014, the first 100 patients were reviewed. Using Deauville score 3 as the cutoff for a complete metabolic response, the overall IOA among the reviewers was good (Krippendorff α = 0.72.) The binary concordance between pairs of reviewers (Cohen κ) ranged from 0.60 to 0.78. The IOA, initially moderate, improved progressively from phase 1 to 4 (Krippendorff α from 0.53 to 0.81; Cohen κ from 0.35-0.72 to 0.77-0.87). Our experience indicates that the agreement among "expert" nuclear physicians reporting PMBCL, even using standardized criteria, was only moderate when the study began. However, agreement improved using a harmonization process, which included a training exercise with discussion of points leading to disagreement and compiling practical rules to sit alongside commonly adopted interpretation criteria.
Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  F-18-FDG PET-CT; Lugano classification; interobserver agreement; primary mediastinal B-cell lymphoma; reading criteria

Mesh:

Year:  2016        PMID: 27545416     DOI: 10.1002/hon.2339

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  6 in total

1.  PET-guided clinical trials in Hodgkin lymphoma: to agree or not to agree, that is the reviewer's question.

Authors:  A Gallamini; M Meignan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-12       Impact factor: 9.236

Review 2.  Influences on PET Quantification and Interpretation.

Authors:  Julian M M Rogasch; Frank Hofheinz; Lutz van Heek; Conrad-Amadeus Voltin; Ronald Boellaard; Carsten Kobe
Journal:  Diagnostics (Basel)       Date:  2022-02-10

Review 3.  FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.

Authors:  Sally F Barrington; Regine Kluge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

Review 4.  The Strategies to Homogenize PET/CT Metrics: The Case of Onco-Haematological Clinical Trials.

Authors:  Stephane Chauvie; Fabrizio Bergesio
Journal:  Biomedicines       Date:  2016-11-15

Review 5.  Primary Mediastinal B-Cell Lymphoma: Novel Precision Therapies and Future Directions.

Authors:  Huan Chen; Tao Pan; Yizi He; Ruolan Zeng; Yajun Li; Liming Yi; Hui Zang; Siwei Chen; Qintong Duan; Ling Xiao; Hui Zhou
Journal:  Front Oncol       Date:  2021-03-22       Impact factor: 6.244

Review 6.  RESISTing the Need to Quantify: Putting Qualitative FDG-PET/CT Tumor Response Assessment Criteria into Daily Practice.

Authors:  J G Peacock; C T Christensen; K P Banks
Journal:  AJNR Am J Neuroradiol       Date:  2019-11-28       Impact factor: 4.966

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.